In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Lexeo Therapeutics, Inc., with a price target of $13.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Mitchell Kapoor has given his Buy rating due to a combination of factors, primarily focusing on the potential of Lexeo Therapeutics’ PKP2 program. Investors see significant upside potential in the program, contingent on the performance of the high-dose cohort. While the low-dose data has not yet met expectations, the high-dose efficacy is anticipated to be a critical determinant of the program’s success. The upcoming update at the January 2026 JPM conference is expected to provide clarity, with the choice of this high-profile venue suggesting confidence in positive outcomes.
Another factor influencing Kapoor’s Buy rating is the safety profile of Lexeo’s candidate, LX2020. Unlike its competitor Rocket’s RP-A601, which has faced safety challenges, LX2020 has demonstrated a remarkable safety profile with no treatment-related serious adverse events. Although there was an SVT event in one patient, it is not considered a dealbreaker, as it may be related to the patient’s prior history of arrhythmias. Investors are closely monitoring this aspect, but the overall safety differentiation gives Lexeo an advantage. Kapoor’s rating reflects optimism that the high-dose data will establish PKP2 as a viable therapeutic option, reinforcing the Buy recommendation.
In another report released on November 5, Chardan Capital also maintained a Buy rating on the stock with a $17.00 price target.